Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug-induced hepatitis.
A patient who had taken erythromycin orally developed mild signs of hepatocellular damage and appeared to became sensitized. After a fortuitous oral intake of the antibiotic, 18 months later, the patient developed an extensive intrahepatic cholestasis. To confirm the allergic nature of this form of hepatitis by demonstrating the presence of serum antibodies directed at the drug. Primary cultured human hepatocytes were used to investigate whether erythromycin can covalently bind to hepatocytes; and to demonstrate the presence of drug-directed immunoglobulins in the serum of the patient. As a consequence of its metabolism by hepatocytes, a small percentage of erythomycin remained bound to hepatocyte proteins. The extent of covalent binding varied among hepatocytes from different donors, and was not observed in metabolically inactive hepatocytes. Antibodies able to bind erythromycin were detected in the serum of the patient. When this serum was added to a human hepatocyte culture that had been previously incubated with the drug, binding of immunoglobulins was observed around the cell membrane and close to pseudo-bile canaliculi, thus indicating the presence of antibodies able to recognize erythromycin-labelled hepatocytes. The existence of serum antibodies directed at erythromycin haptens in this patient strongly suggests an allergic mechanism for this drug-induced hepatitis.